The genomic landscape of endocrine-resistant advanced breast cancers
We integrated the genomic sequencing of 1,918 breast cancers, including 1,501 hormone
receptor-positive tumors, with detailed clinical information and treatment outcomes. In 692 …
receptor-positive tumors, with detailed clinical information and treatment outcomes. In 692 …
[HTML][HTML] Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms …
DM Merino, LM McShane, D Fabrizio… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background Tumor mutational burden (TMB), defined as the number of somatic mutations
per megabase of interrogated genomic sequence, demonstrates predictive biomarker …
per megabase of interrogated genomic sequence, demonstrates predictive biomarker …
A rectal cancer organoid platform to study individual responses to chemoradiation
Rectal cancer (RC) is a challenging disease to treat that requires chemotherapy, radiation
and surgery to optimize outcomes for individual patients. No accurate model of RC exists to …
and surgery to optimize outcomes for individual patients. No accurate model of RC exists to …
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
G Vlachogiannis, S Hedayat, A Vatsiou, Y Jamin… - Science, 2018 - science.org
Patient-derived organoids (PDOs) have recently emerged as robust preclinical models;
however, their potential to predict clinical outcomes in patients has remained unclear. We …
however, their potential to predict clinical outcomes in patients has remained unclear. We …
The association between tumor mutational burden and prognosis is dependent on treatment context
In multiple cancer types, high tumor mutational burden (TMB) is associated with longer
survival after treatment with immune checkpoint inhibitors (ICIs). The association of TMB with …
survival after treatment with immune checkpoint inhibitors (ICIs). The association of TMB with …
Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade
Importance The anti–programmed cell death protein 1 (PD-1) antibody pembrolizumab is
approved by the US Food and Drug Administration for the treatment of microsatellite …
approved by the US Food and Drug Administration for the treatment of microsatellite …
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
V Amodio, R Yaeger, P Arcella, C Cancelliere… - Cancer discovery, 2020 - AACR
Most patients with KRAS G12C–mutant non–small cell lung cancer (NSCLC) experience
clinical benefit from selective KRASG12C inhibition, whereas patients with colorectal cancer …
clinical benefit from selective KRASG12C inhibition, whereas patients with colorectal cancer …
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
Background Addition of trastuzumab to first-line chemotherapy improves overall survival in
patients with HER2-positive metastatic gastric cancer. We assessed the safety and activity of …
patients with HER2-positive metastatic gastric cancer. We assessed the safety and activity of …
Molecular determinants of response to anti–programmed cell death (PD)-1 and anti–programmed death-ligand 1 (PD-L1) blockade in patients with non–small-cell …
Purpose Treatment of advanced non–small-cell lung cancer with immune checkpoint
inhibitors (ICIs) is characterized by durable responses and improved survival in a subset of …
inhibitors (ICIs) is characterized by durable responses and improved survival in a subset of …
[HTML][HTML] Genomic hallmarks and structural variation in metastatic prostate cancer
While mutations affecting protein-coding regions have been examined across many
cancers, structural variants at the genome-wide level are still poorly defined. Through …
cancers, structural variants at the genome-wide level are still poorly defined. Through …